Last reviewed · How we verify
AC-1202 mixed in water
AC-1202 mixed in water is a Medical food / Ketogenic agent Small molecule drug developed by Cerecin. It is currently in Phase 1 development.
Provides medium-chain triglycerides that are metabolized to ketone bodies, offering an alternative energy source for brain cells with impaired glucose metabolism.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AC-1202 mixed in water |
|---|---|
| Sponsor | Cerecin |
| Drug class | Medical food / Ketogenic agent |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
AC-1202 contains caprylic triglyceride, which is converted in the liver to ketone bodies (primarily beta-hydroxybutyrate). These ketones can cross the blood-brain barrier and provide an alternative fuel source for neurons in conditions where glucose metabolism is compromised, such as Alzheimer's disease.
Approved indications
Common side effects
Key clinical trials
- Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides (PHASE1)
- Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production (PHASE1)
- Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AC-1202 mixed in water CI brief — competitive landscape report
- AC-1202 mixed in water updates RSS · CI watch RSS
- Cerecin portfolio CI
Frequently asked questions about AC-1202 mixed in water
What is AC-1202 mixed in water?
How does AC-1202 mixed in water work?
Who makes AC-1202 mixed in water?
What drug class is AC-1202 mixed in water in?
What development phase is AC-1202 mixed in water in?
Related
- Drug class: All Medical food / Ketogenic agent drugs
- Manufacturer: Cerecin — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing